[1]郄 鹏,聂小栋,殷其凡,等.老年局部晚期食管癌病人新辅助化疗剂量与肌少症的关系[J].肠外与肠内营养杂志,2024,(06):334-340.[doi:10.16151/j.1007-810x.2024.06.003]
　QIE Peng,NIE Xiao-dong,YIN Qi-fan,et al.Relationship between neoadjuvant chemotherapy dose and sarcopenia in elderly patients with locally advanced esophageal cancer[J].PARENTERAL & ENTERAL NUTRITION,2024,(06):334-340.[doi:10.16151/j.1007-810x.2024.06.003]
点击复制

老年局部晚期食管癌病人新辅助化疗剂量与肌少症的关系()
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2024年06期
页码:
334-340
栏目:
论著
出版日期:
2024-12-10

文章信息/Info

Title:
Relationship between neoadjuvant chemotherapy dose and sarcopenia in elderly patients with locally advanced esophageal cancer
作者:
郄 鹏1 ; 聂小栋2; 殷其凡1; 崔红赏1; 王会恩1
1.河北省人民医院胸外一科，河北石家庄050051；2.河北医科大学第二医院营养科，河北石家庄 050051
Author(s):
QIE Peng1;  NIE Xiao-dong2;  YIN Qi-fan1;  CUI Hong-shang1;  WANG Hui-en1
1. Department of Thoracic Surgery, Hebei General hospital, Shijiazhuang 050051, Hebei, China；2. Department of Nutrition, The Second Hospital of Hebei Medical University, Shijiazhuang 050051,Hebei, China
关键词:
局部晚期食管癌 ; 肌少症 ; 新辅助化疗 ; 相对剂量强度
Keywords:
Locally advanced esophageal cancer;  Sarcopenia;  Neoadjuvant chemotherapy;  Relative dose intensity
分类号:
R459.3
DOI:
10.16151/j.1007-810x.2024.06.003
文献标志码:
A
摘要:
目的：探讨老年局部晚期食管癌（LAEC）病人肌少症与新辅助化疗（NAC）药物相对剂量强度（RDI）的关系。 方法：采用回顾性队列研究，收集2018年1月至2020年12月河北省人民医院胸外一科年龄≥65岁在NAC后接受根治性食管癌切除术的LAEC 病人临床资料。根据第三腰椎（L3）水平的计算机断层扫描图像计算骨骼肌质量指数。采用骨骼肌质量的 Youden 指数定义肌少症。根据药物的实际剂量强度和标准剂量强度计算平均药物相对剂量。通过多因素Logistic回归分析病人低RDI的独立影响因素，采用Cox生存分析评估低RDI对预后的影响。 结果：本研究共纳入了126名老LAEC病人，肌少症46人，非肌少症80人，平均年龄为 71.3 岁。经过调整年龄、性别、体质量指数、药物治疗方案、临床分期和肌酐清除率等因素, 肌少症与低平均药物相对剂量相关（OR：2.193，95%CI：1.107 ~ 4.411，P = 0.022）。第一个化疗周期后，与非肌少症病人相比，由于中性粒细胞减少，平均RDI 较低的肌少症病人减少化疗剂量、延迟或停药的比例较高（41.9% vs 39.0%），并且体能状态下降显著（9.7% vs0）。调整年龄、性别、CCI等因素影响后，低平均化疗RDI是病人的无复发生存（RFS）的独立影响因子。 结论：老年局部晚期食管癌病人，肌少症会降低新辅助化疗平均RDI，治疗前应常规进行筛查评估。肌少症可能成为改善食管癌病人临床结局的一个指标。
Abstract:
Objective: To explore the relationship between the relative dose intensity of neoadjuvant chemotherapy drugs and the sarcopenia in elderly patients with locally advanced esophageal cancer (LAEC). Methods: A retrospective cohort study was conducted between January 2018 and December 2020 in the Department of Thoracic Surgery, Hebei General hospital. A total of 126 LAEC patients aged ≥65 years who underwent radical esophageal cancer resection after NAC were enrolled in this study. Skeletal muscle mass index was calculated from computed tomography(CT) images at the level of the third lumbar vertebra (L3). Sarcopenia was defined using the Youden index of skeletal muscle mass. The average relative dose of the drug was calculated basing on the actual dose intensity and standard dose intensity of the drug. Multivariate Logistic regression was used to analyze the independent risk factors of low relative dose intensity (RDI), and Cox survival analysis was used to evaluate the effect of low RDI on prognosis. Results: 126 patients were retrospectively analyzed, in which 46 patients had sarcopenia and 80 patients had no sarcopenia. The presence of sarcopenia was associated with low RDI and was varied following age, gender, body mass index, drug treatment regimen, clinical stage and creatinine clearance (OR: 2.193, 95%CI: 1.107 ~ 4.411, P = 0.022). After the first cycle of chemotherapy, sarcopenic patients with a lower mean RDI had a higher rate of chemotherapy dose reduction, delay, or discontinuation due to neutropenia compared with non-sarcopenic patients (41.9% vs 39.0%), and the physical fitness was significantly declined (9.7% vs 0%). Low average RDI was an independent influencing factor for recurrencefree survival in the patients. Conclusions: Sarcopenia could be a predictor for reduced mean RDI of NAC in elderly patients with LAEC. The findings have implications for improving the clinical outcomes of patients with esophageal cancer.

参考文献/References:


[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018, 68(6): 394-424.
[2] Stiles BM, Kamel MK, Harrison SW, et al. Neoadjuvant therapy for locally advanced esophageal cancer should be targeted to tumor histology[J]. Ann Thorac Surg, 2019, 107(1): 187-193.
[3] Saeki H, Sohda M, Sakai M, et al. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma[J]. Ann Gastroenterol Surg, 2020, 4(5): 490-497.
[4] Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004.
[5] Keditsu KK, Jiwnani S, Karimundackal G, et al. Multimodality management of esophageal cancer[J]. Indian J Surg Oncol, 2013, 4(2): 96-104.
[6] Li JY, Ma SH. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer[J]. Thorac Cancer, 2021, 12(17): 2293-2299.
[7] 谢 雅, 闫文锋, 夏晓博, 等. 肌少症对食管胃结合部腺癌患者生命质量的影响[J]. 中华消化外科杂志, 2023, 22(11): 1330-1336.
[8] 张 亮, 郑 鹏. L3水平CT横截面机体组成改变对结直肠癌病人生存预后的价值分析[J]. 肠外与肠内营养, 2023, 30(4):226-233.
[9] 田 浩, 周 达, 叶 晨, 等. 术前肌肉减少症对胃癌病人临床预后的影响:一项前瞻性队列研究[J]. 肠外与肠内营养, 2018,25(3): 166-170, 175.
[10] Fujita S, Sakuramoto S, Matsui K, et al. Relative dose intensity and 1-year psoas muscle index reduction rate as prognostic factors in gastric cancer patients with postoperative adjuvantchemotherapy[J]. Int J Clin Oncol, 2023, 28(1): 110-120.
[11] Bland KA, Zadravec K, Landry T, et al. Impact of exercise on chemotherapy completion rate: a systematic review of the evidence and recommendations for future exercise oncologyresearch[J]. Crit Rev Oncol Hematol, 2019, 136: 79-85.
[12] Yamashita K, Watanabe M, Mine S, et al. The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curativeintent[J]. Surg Today, 2018, 48(6): 632-639.
[13] Huang Y, Feng JF, Liu JS, et al. Prognostic role of serum Creactive protein in esophageal cancer: a systematic review and meta-analysis[J]. Ther Clin Risk Manag, 2015, 11: 89-94.
[14] 卓嘉璐, 李子祥, 韩 婷. 预后营养指数与相位角在结直肠肿瘤病人营养不良诊断中的价值[J]. 肠外与肠内营养, 2022, 29(3):129-134.
[15] Katayama H, Kurokawa Y, Nakamura K, et al. Extended claviendindo classification of surgical complications: Japan clinical oncology group postoperative complications criteria[J]. Surg Today, 2016, 46(6): 668-685.
[16] Weycker D, Barron R, Edelsberg J, et al. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice[J]. Breast Cancer Res Treat, 2012, 133(1): 301-310.
[17] Pécsi B, Mangel L. Real-life effectivity of dose intensity reduction of first-line mFOLFIRI-based treatment of metastatic colorectal cancers: sometimes less is more[J]. Curr Oncol, 2023, 30(1): 908-922.
[18] Gr?nberg BH, Valan CD, Halvorsen T, et al. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients[J]. J Cachexia Sarcopenia Muscle, 2019, 10(6): 1347-1355.
[19] Kuo CFJ, Ke BH, Wu NY, et al. Prognostic value of tumor volume for patients with advanced lung cancer treated with chemotherapy[J]. Comput Methods Programs Biomed, 2017, 144:165-177.
[20] Matsuda S, Kawakubo H, Okamura A, et al. Prognostic significance of stratification using pathological stage and response to neoadjuvant chemotherapy for esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2021, 28(13): 8438-8447.
[21] Cruz-Jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[22] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people[J]. Age Ageing, 2010, 39(4): 412-423.
[23] Francis KE, Kim SI, Friedlander M, et al. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer[J]. Ann Oncol, 2022, 33(6): 593-601.
[24] Huang CH, Lue KH, Hsieh TC, et al. Association between sarcopenia and clinical outcomes in patients with esophageal cancer under neoadjuvant therapy[J]. Anticancer Res, 2020, 40(2): 1175-1181.
[25] Navarrete-Villanueva D, Gómez-Cabello A, Marín-Puyalto J, et al. Frailty and physical fitness in elderly people: a systematic review and meta-analysis[J]. Sports Med, 2021, 51(1): 143-160.
[26] Petermann-Rocha F, Gray SR, Pell JP, et al. The joint association of sarcopenia and frailty with incidence and mortality health outcomes: a prospective study[J]. Clin Nutr, 2021, 40(4): 2427-2434.
[27] Liao CD, Chen HC, Huang SW, et al. The role of muscle mass gain following protein supplementation plus exercise therapy in older adults with sarcopenia and frailty risks: a systematic review and meta-regression analysis of randomized trials[J]. Nutrients, 2019, 11(8): 1713.

相似文献/References:

[1]吴 丹,陈强谱.慢性阻塞性肺疾病相关肌少症的诊断与治疗[J].肠外与肠内营养杂志,2021,(05):308.[doi:10.16151/j.1007-810x.2021.05.010]
　WU Dan,CHEN Qiang-pu.Diagnosis and treatment of chronic obstructive pulmonary disease-related sarcopenia[J].PARENTERAL & ENTERAL NUTRITION,2021,(06):308.[doi:10.16151/j.1007-810x.2021.05.010]
[2]严 玮,叶向红,王 敏,等.1例创伤后多发肠瘘、腹壁缺损并肌少症病儿的治疗与护理[J].肠外与肠内营养杂志,2021,(05):317.[doi:10.16151/j.1007-810x.2021.05.012]
[3]陈新宇,周军良,李婷婷,等.相位角与老年肌少症的关系研究[J].肠外与肠内营养杂志,2021,(05):275.[doi:10.16151/j.1007-810x.2021.05.004]
　CHEN Xin-yu,ZHOU Jun-liang,LI Ting-ting,et al.Association of phase angle with sarcopenia in elderly adults[J].PARENTERAL & ENTERAL NUTRITION,2021,(06):275.[doi:10.16151/j.1007-810x.2021.05.004]
[4]张佩彦,秦肖含,王玉珍.肌少症与肝硬化的研究进展[J].肠外与肠内营养杂志,2022,(01):57.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
　ZHANG Pei-yan,QIN Xiao-han,WANG Yu-zhen.Research progress of sarcopenia in patients with cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2022,(06):57.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
[5]韩 雨,杨 洋,叶向红,等.老年恶性肿瘤病人衰弱与肌少症关系的研究进展[J].肠外与肠内营养杂志,2022,(04):248.[doi:10.16151/j.1007-810x.2022.04.010]
　HAN Yu,YANG Yang,YE Xiang-hong,et al.Research progress on the relationship between frailty and sarcopenia in elderly patients with malignant tumors[J].PARENTERAL & ENTERAL NUTRITION,2022,(06):248.[doi:10.16151/j.1007-810x.2022.04.010]
[6]沈 雷,王俊杰,韩 军,等.胃癌病人术前甲状腺激素水平与肌少症的相关性研究[J].肠外与肠内营养杂志,2022,(05):257.[doi:10.16151/j.1007-810x.2022.05.001]
　SHEN Lei,WANG Jun-jie,HAN Jun,et al.Association of thyroid function with sarcopenia in patients with gastric cancer[J].PARENTERAL & ENTERAL NUTRITION,2022,(06):257.[doi:10.16151/j.1007-810x.2022.05.001]
[7]董丹妮,楚 翘,项 密,等.肺癌病人合并肌少症研究进展[J].肠外与肠内营养杂志,2024,(03):184.[doi:DOI : 10.16151/j.1007-810x.2024.03.010]
　DONG Dan-ni,CHU Qiao,XIANG Mi,et al.Research progress on sarcopenia in patients with lung cancer[J].PARENTERAL & ENTERAL NUTRITION,2024,(06):184.[doi:DOI : 10.16151/j.1007-810x.2024.03.010]
[8]张雪静,顾启红,程梦瑶,等.结直肠癌病人肌肉减少症风险预测模型的构建及验证[J].肠外与肠内营养杂志,2024,(06):346.[doi:10.16151/j.1007-810x.2024.06.005]
　ZHANG Xue-jing,GU Qi-hong,CHENG Meng-yao,et al.Construction and validation of a risk prediction model for sarcopenia in colorectal cancer patients[J].PARENTERAL & ENTERAL NUTRITION,2024,(06):346.[doi:10.16151/j.1007-810x.2024.06.005]

备注/Memo

备注/Memo:
基金项目 ：河北省医学重点科技研究计划（20240624）作者简介 ：郄 鹏，主治医师，主要从事食管疾病的临床研究，微创诊治。E-mail：qiepeng2004@163.com通讯作者 ：王会恩，E-mail：wanghe829@126.com
更新日期/Last Update: 1900-01-01